Table 4. KF41399 effects on antitumor... | American Society of Hematology

Table 4.

KF41399 effects on antitumor activity of ACNU against Sarcoma 180 inoculated into DDY mice

Group	Dose (mg/kg)	Schedule (day)	T/C^4-150 (%)	Body weight^4-151 (g)	Mortality	Platelet counts (×10⁴/μL^‡)
Control			100	−0.7	0/5	120.8 ± 12.0
KF41399	25 (PO)	0-1	115	−1.2	0/5	114.3 ± 16.4
ACNU	45 (IV)	2-3	24	−4.5	0/5	55.6 ± 24.3
KF41399 + ACNU	25 (PO)	0-1
	45 (IV)	2-3	24	−2.2	0/5	77.2 ± 14.3

Group	Dose (mg/kg)	Schedule (day)	T/C^4-150 (%)	Body weight^4-151 (g)	Mortality	Platelet counts (×10⁴/μL^‡)
Control			100	−0.7	0/5	120.8 ± 12.0
KF41399	25 (PO)	0-1	115	−1.2	0/5	114.3 ± 16.4
ACNU	45 (IV)	2-3	24	−4.5	0/5	55.6 ± 24.3
KF41399 + ACNU	25 (PO)	0-1
	45 (IV)	2-3	24	−2.2	0/5	77.2 ± 14.3

PO, oral; IV, intravenous.

Sarcoma 180 cells (8-mm³ fragment) were inoculated into DDY mice. When tumors grew to a size between 50 and 300 mm³, therapy was initiated.

Minimum T/C;

maximum body weight change;

platelet counts on day 10.